NATALIE WISE: Open Payments
NPI 1801227392 · TRAVERSE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$652 in 35 payments from 15 companies in 2025. Trend: 2023 $725 · 2024 $528 · 2025 $652
Food & beverage: $652
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $171 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $68 |
| Vanda Pharmaceuticals Inc. | 2 | $68 |
| Astellas Pharma US Inc | 2 | $43 |
| Indivior Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Novo Nordisk Inc | 2 | $36 |
| Braeburn Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 |
Products named: QULIPTA, VRAYLAR, CAPLYTA, FANAPT, Veozah, SUBLOCADE, Auvelity, Ozempic.
Industry payments across MI — which companies pay providers there.
